<DOC>
	<DOCNO>NCT02555397</DOCNO>
	<brief_summary>The primary purpose phase 1 study determine dose-dependent toxicity maximum tolerate dose ( MTD ) oncolytic adenovirus-mediated cytotoxic IL-12 gene therapy men locally recurrent prostate cancer definitive radiotherapy</brief_summary>
	<brief_title>Phase 1 Trial Interleukin 12 Gene Therapy Locally Recurrent Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>Biopsyproven local recurrence prostate cancer least one year completion definitive radiation therapy Evidence biologically active disease demonstrate unequivocally rise serum PSA level ≥ 2 ng/mL nadir PSA &lt; 100 ng/mL Age ≥ 18 year Karnofsky performance status ≥ 70 Negative lymph nondes establish image ( pelvic CT pelvic MRI ) No evidence metastatic disease , evaluate bone scan CT scan abdomen pelvis . Subjects must adequate baseline organ function assess follow laboratory value : Adequate renal function serum creatinine ≤ 1.5 mg/dL Platelet count &gt; 100,000/µL Absolute neutrophil count &gt; 1,000/µL Hemoglobin &gt; 10.0 g/dL Bilirubin &gt; 1.5 mg/dL AST/SGOT ALT/SGPT &lt; 3.0 time upper limit normal ( ULN ) Men childproducing potential must willing consent use effective contraception least 3 month gene therapy Subjects must possess ability give inform consent express willingness meet expect requirement protocol duration study PSA ≥ 100 ng/mL Prostate volume &gt; 100 cc Pathologically positive lymph node node &gt; 1.0 cm imaging ( nodes &gt; 1.0 cm biopsy negative allow . Evidence M1 metastatic disease Prior invasive malignancy except nonmelanoma skin cancer within 5 year enrollment . Subjects must diseasefree &gt; 5 year Prior radical prostatectomy , cryosurgery prostate cancer , bilateral orchiectomy reason If subject prior androgen deprivation therapy ( ADT ) , subject exhibit biochemical failure ADT Prior systemic chemotherapy study cancer ( prior chemotherapy different cancer allow ; however , subject must &gt; 2 year postcompletion chemotherapy time registration . Subjects Proscar therapy must stop eligible ) Major surgery plan within 3 month registration Severe , active comorbidity define : New York Health Association Class II great congestive heart failure active ventricular arrhythmia require medication Chronic obstructive pulmonary disease ( COPD ) exacerbation respiratory illness require hospitalization within last 3 month preclude study therapy time registration Acute infection Previous history liver disease include hepatitis Immunosuppressive therapy include systemic corticosteroid ( use inhale topical corticosteroid permit ) Impaired immunity susceptibility serious viral infection Allergy product use protocol . If subject allergy Ciproflaxin , another antibiotic substitute discretion treat physician Serious medical psychiatric illiness concomitant medication , , judgement principal investigator , might interfere subject 's ability respond tolerate treatment complete trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Locally Recurrent</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>IL-12</keyword>
	<keyword>Adenovirus</keyword>
</DOC>